No significant differences in PFS were found between the high-progression-risk patients in the EGFR-TKI cohort and the patients with EGFR variant–positive or EGFR wild-type NSCLC receiving chemotherapy (median PFS, 6.9 vs 4.4 months; P = .08). Here, EGFR is linked to non-small cell lung carcinoma.